Clinical tumour sequencing for precision oncology: time for a universal strategy

Michael L Cheng; Michael F Berger; David M Hyman; David B Solit

doi:10.1038/s41568-018-0043-2

Clinical tumour sequencing for precision oncology: time for a universal strategy

Nat Rev Cancer. 2018 Sep;18(9):527-528. doi: 10.1038/s41568-018-0043-2.

Authors

Michael L Cheng¹, Michael F Berger^{2

3}, David M Hyman¹, David B Solit^{4

5}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
² Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
⁵ Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].

Abstract

Routine, comprehensive molecular characterization of patient tumours has the potential to accelerate therapeutic advances and inform cancer biology. Here, we describe insights from the implementation of an enterprise-wide, prospective clinical sequencing strategy at an academic cancer centre.

MeSH terms

Brain Neoplasms
Colorectal Neoplasms
Exome Sequencing
High-Throughput Nucleotide Sequencing
Humans
Medical Oncology
Microsatellite Instability
Neoplasms / genetics*
Neoplasms / therapy
Neoplastic Syndromes, Hereditary
Precision Medicine / methods*
Sequence Analysis, DNA

Supplementary concepts

Turcot syndrome

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States